Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partners

Genmab A/S (NASDAQ:GMAB) was upgraded by research analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a research note issued to investors on Thursday,Briefing.com Automated Import reports. The firm currently has a $27.00 target price on the stock. Leerink Partners’ price objective suggests a potential upside of 37.13% from the company’s current price.

A number of other research firms have also commented on GMAB. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.17.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $19.69 on Thursday. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88. The firm has a market capitalization of $13.03 billion, a PE ratio of 19.12, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The business’s fifty day moving average price is $20.72 and its 200 day moving average price is $23.24.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. As a group, equities analysts anticipate that Genmab A/S will post 1.25 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.